Variation in use of high-cost diabetes mellitus medications in the VA healthcare system

Archives of Internal Medicine

Volumn 172, Issue 20, 2012, Pages 1608-1609

  Gellad, Walid ^a,b,e   Mor, Maria ^a,c   Zhao, Xinhua ^a   Donohue, Julie ^d   Good, Chester ^a,b,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e RAND CORPORATION   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; VETERAN;

DIABETES MELLITUS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84869102683     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.4482     Document Type: Article

References (9)

1. Trivedi AN, Matula S, Miake-Lye I, Glassman PA, Shekelle P, Asch S. Systematic review: comparison of the quality of medical care in Veterans Affairs and non-Veterans Affairs settings. Med Care. 2011;49(1):76-88.
2. Donohue JM, Morden NE, Gellad WF, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med. 2012;366(6):530-538.
3. Miller DR, Safford MM, Pogach LM. Who has diabetes? best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(suppl 2):B10-B21. (Pubitemid 38569259)
4. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386-399. (Pubitemid 351664540)
5. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS). Optimal Therapy Recommendations for the Prescribing and Use of Insulin Analogues. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2009.
6. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613.
7. National Institute for Health and Clinical Excellence (NICE). The Clinical Effectiveness and Cost Effectiveness of Long-acting Insulin Analogues for Diabetes. London, England: NICE; 2002.
8. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6): 613-619.
9. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Aff (Millwood). 2003;22(3):149-158. (Pubitemid 41388751)